PMID- 35316480
OWN - NLM
STAT- MEDLINE
DCOM- 20220411
LR  - 20220718
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 23
IP  - 4
DP  - 2022 Apr
TI  - Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and 
      Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
PG  - 609-629
LID - 10.1007/s11864-022-00966-0 [doi]
AB  - The treatment of renal cell carcinoma (RCC) is one of the great success stories 
      in the field of oncology, which was revolutionized with the development of 
      therapies aimed at disrupting crucial pathways. Tumor biology of RCC has provided 
      insight into the disease through elucidation of the role of vascular endothelial 
      growth-factor (VEGF) and the mammalian target of rapamycin (mTOR). Targeted 
      agents against VEGF and mTOR, as well as agents targeting relevant 
      immunomodulatory pathways, have shown clinical benefit for advanced disease. The 
      targeted agents are highly effective in achieving a response and survival, 
      particularly in high-risk patients. These include the vascular endothelial growth 
      factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) axitinib and 
      cabozantinib, and programmed cell death 1 protein (PD-1) immune checkpoint 
      inhibitors (ICI) nivolumab and pembrolizumab. There is a wealth of evidence 
      investigating different therapeutic options and combinations for first-line 
      treatment of advanced RCC including the CheckMate 214 study, KEYNOTE-426, JAVELIN 
      Renal 101, and CheckMate 9ER. Dual ICI and combination agents targeting the 
      programmed cell death protein 1/programmed cell death protein ligand 1 (PD1/PDL1) 
      and VEGF, began to demonstrate superiority over previously accepted standards in 
      advanced clear-cell RCC. Data from a number of clinical studies are available to 
      help physicians with evidence-based decisions for the sequence of second-line and 
      future treatments for patients with progressive RCC. In this review, we focus on 
      essentials for clinicians treating patients with clear-cell RCC.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Cetin, Bulent
AU  - Cetin B
AUID- ORCID: 0000-0001-8628-0864
AD  - Department of Internal Medicine, Division of Medical Oncology, Suleyman Demirel 
      University Faculty of Medicine, 32260, Isparta, Turkey. caretta06@hotmail.com.
FAU - Wabl, Chiara A
AU  - Wabl CA
AD  - University of California, San Francisco School of Medicine, San Francisco, USA.
FAU - Gumusay, Ozge
AU  - Gumusay O
AD  - University of California Helen Diller Family Comprehensive Cancer Center, San 
      Francisco, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220322
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 31YO63LBSN (Nivolumab)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Carcinoma, Renal Cell/drug therapy/etiology
MH  - Humans
MH  - *Kidney Neoplasms/drug therapy/etiology
MH  - Nivolumab/therapeutic use
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases
MH  - Vascular Endothelial Growth Factor A
OTO - NOTNLM
OT  - Immunotherapy
OT  - Metastatic renal cell carcinoma
OT  - Tyrosine kinase inhibitors
EDAT- 2022/03/23 06:00
MHDA- 2022/04/12 06:00
CRDT- 2022/03/22 17:18
PHST- 2022/03/02 00:00 [accepted]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/04/12 06:00 [medline]
PHST- 2022/03/22 17:18 [entrez]
AID - 10.1007/s11864-022-00966-0 [pii]
AID - 10.1007/s11864-022-00966-0 [doi]
PST - ppublish
SO  - Curr Treat Options Oncol. 2022 Apr;23(4):609-629. doi: 
      10.1007/s11864-022-00966-0. Epub 2022 Mar 22.